Skip to main content
padlock icon - secure page this page is secure

Economic evaluation of arsenic trioxide compared to all‐trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada

Buy Article:

$52.00 + tax (Refund Policy)

Acute promyelocytic leukemia (APL) is an uncommon type of acute leukemia characterized by high early mortality. Current first‐line treatments include all‐trans retinoic acid (ATRA), anthracyclines, and other conventional chemotherapies (CTs). Although APL is generally associated with a good prognosis, about 20% of patients who achieve remission subsequently relapse and are resistant to the previously administrated treatment. The objective of this study was to assess, from a Canadian perspective, the economic impact of arsenic trioxide (ATO) compared to ATRA+CT for treatment of patients with relapsed/refractory APL.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Canada; acute promyelocytic leukemia; all‐trans retinoic acid; arsenic trioxide; cost‐effectiveness; cost‐utility

Document Type: Research Article

Publication date: September 1, 2015

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more